Pomerantz LLP is investigating EyePoint, Inc. for potential securities fraud following the company's disclosure of disappointing Phase 3 clinical trial results for its wet AMD treatment, DURAVYU™. This led to the termination of the program and a significant workforce reduction, indicating a major setback for the company's pipeline and financial health.
Pomerantz LLP has initiated an investigation into EyePoint, Inc. for potential securities fraud. This follows EyePoint's announcement of disappointing Phase 3 clinical trial results for its key wet AMD treatment, DURAVYU™, which subsequently led to the termination of the entire late-stage wet AMD program and a 53% workforce reduction. This is a significant negative development for EyePoint, as it indicates a major failure in its drug development pipeline and substantial operational restructuring. For traders, this signals increased legal and financial risk for EYPT in the short-to-medium term, potentially leading to further stock price volatility and downward pressure as the investigation unfolds and the company navigates the fallout from its failed clinical trials.